Trials / Completed
CompletedNCT04590144
Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 446 (actual)
- Sponsor
- MicroPort CRM · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to assess the safety and key electrical performance of the INVICTA leads equipped with DF4 connector: ACTIVE fixation type models (single and dual coil: INVICTA 1CR, INVICTA 2CR)
Detailed description
APOLLO study is a pre-market approval (INVICTA leads - devices under investigation - are not CE marked), interventional, prospective, longitudinal, international (European), multicenter, single arm study. The devices under investigation, the INVICTA defibrillation leads, are new quadripolar leads, to be used with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators (ICD/CRT-D). This clinical study intends to demonstrate safety and electrical performances of the INVICTA leads among the different models: active fixation either single coil (model 1CR) or dual coil (model 2CR)leads models. The clinical data will be used to support the application to CE marking of INVICTA leads. The primary endpoints will be evaluated at 3 months post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation. A total number of 445 patients will be enrolled in the study, in up to 60 centers in Europe. The follow-up visits are scheduled at hospital discharge, at 1 month, at 3 months, at 6 months, at 12 months, at 18 months and at 24 months, post-implant
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | INVICTA lead | The implant or the attempt to implant an INVICTA lead |
Timeline
- Start date
- 2021-06-04
- Primary completion
- 2022-03-16
- Completion
- 2024-12-23
- First posted
- 2020-10-19
- Last updated
- 2025-07-24
Locations
45 sites across 8 countries: Austria, France, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04590144. Inclusion in this directory is not an endorsement.